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Abstract
Introduction: Recent advances in molecular diagnostics allow diffuse gliomas to be classified based on their
genetic changes into distinct prognostic subtypes. However, a systematic analysis of all molecular markers has thus
far not been performed; most classification schemes use a predefined and select set of genes/molecular markers.
Here, we have analysed the TCGA dataset (combined glioblastoma (GBM) and lower grade glioma (LGG) datasets)
to identify all prognostic genetic markers in diffuse gliomas in order to generate a comprehensive classification
scheme.
Results: Of the molecular markers investigated (all genes mutated at a population frequency >1.7 % and frequent
chromosomal imbalances) in the entire glioma dataset, 57 were significantly associated with overall survival. Of
these, IDH1 or IDH2 mutations are associated with lowest hazard ratio, which confirms IDH as the most important
prognostic marker in diffuse gliomas. Subsequent subgroup analysis largely confirms many of the currently used
molecular classification schemes for diffuse gliomas (ATRX or TP53 mutations, 1p19q codeletion). Our analysis also
identified PI3-kinase mutations as markers of poor prognosis in IDH-mutated + ATRX/TP53 mutated diffuse gliomas,
median survival 3.7 v. 6.3 years (P = 0.02, Hazard rate (HR) 2.93, 95 % confidence interval (CI) 1.16 – 7.38). PI3-kinase
mutations were also prognostic in two independent datasets. In our analysis, no additional molecular markers were
identified that further refine the molecular classification of diffuse gliomas. Interestingly, these molecular classifiers
do not fully explain the variability in survival observed for diffuse glioma patients. We demonstrate that tumor
grade remains an important prognostic factor for overall survival in diffuse gliomas, even within molecular glioma
subtypes. Tumor grade was correlated with the mutational load (the number of non-silent mutations) of the tumor:
grade II diffuse gliomas harbour fewer genetic changes than grade III or IV, even within defined molecular subtypes
(e.g. ATRX mutated diffuse gliomas).
Conclusion: We have identified PI3K mutations as novel prognostic markers in gliomas. We also demonstrate that
the mutational load is associated with tumor grade. The increase in mutational load may partially explain the
increased aggressiveness of higher grade diffuse gliomas when a subset of the affected genes actively contributes
to gliomagenesis and/or progression.
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Introduction
Gliomas are the most common primary malignant brain
tumors in adults [1, 2]. Diffuse gliomas are classified into
different subtypes according to their histological features
into astrocytomas, oligodendrogliomas and mixed oli-
goastrocytomas [3]. These subtypes are further divided
into various tumor grades (grade II-IV) depending on
the number of malignant features present in the tumor
(nuclear atypia, mitoses, endothelial proliferation and
necrosis). The WHO classification, in combination with
clinical parameters such as age and Karnofsky Perform-
ance Status (KPS), guides treatment decisions and pro-
vides prognostic information for patients and clinicians.
Unravelling the causal genetic changes of diffuse gli-
omas has been the focus of extensive research in the past
decade [4–6] and it is now possible to classify diffuse gli-
omas based on their molecular characteristics [7–11]. For
example, IDH1 mutations are frequent events in all grade
II and III gliomas and in secondary glioblastomas (sGBM,
glioblastomas that progress from lower grade gliomas)
whereas primary GBMs (pGBM) are usually IDHwt and
frequently have genetic changes involving the EGFR locus,
PTEN deletions and TERT promoter mutations [4, 6, 12].
In addition, CIC, FUBP1, TERT promoter mutations and
1p/19q codeletion are observed more frequently in oligo-
dendrogliomas than in astrocytic tumors [13–15] whereas
ATRX and TP53 mutations are seen more frequently in
grade II/III astrocytic tumors [16–18]. The importance of
this molecular information is widely acknowledged and
guidelines have been made to incorporate them in the
WHO classification of gliomas [19].
Although the genetic changes are used to classify diffuse
gliomas into distinct prognostic subtypes [9, 10, 16, 20–23],
a systematic analysis of all available molecular prognostic
markers has thusfar not been performed. In fact, most
classification schemes use only a few high frequent genes
or molecular markers. It is therefore possible that add-
itional and/or stronger prognostic markers are present
that can improve the molecular classification of diffuse
gliomas. Furthermore, while the prognostic molecular
markers may refine (or even replace) the histological clas-
sification of diffuse gliomas, there are thusfar no genetic
changes that can discriminate between grade II and III
tumors. This is remarkable as tumor grade is a strong
prognostic marker in diffuse gliomas [3] (although some
reports found little prognostic value for tumor grade
within defined glioma subtypes [24, 25]).
In this study we therefore have analyzed the publicly
available TCGA dataset in order to identify additional
prognostic molecular markers in diffuse gliomas. Since
diffuse gliomas can be classified solely based on molecu-
lar markers [9, 20], we also evaluated whether tumor
grade remains relevant after the molecular classification
and/or whether there are genetic markers that can
distinguish between tumor grades in diffuse gliomas.
Our analysis confirms many of the currently used molecu-
lar classification schemes for diffuse gliomas: gliomas are
first separated based on IDH-mutation status and a fur-
ther stratification is based on ATRX/TP53 mutation status
or 1p19q codeletion. We show that PI3-kinase mutations
are associated with poor prognosis in molecular astrocyto-
mas (i.e. diffuse gliomas that are IDH-mutated and 1p19q
intact (or ATRX/TP53mutated)) and that no other marker
investigated in this study appears to further refine this
molecular/prognostic classification of diffuse gliomas. Our
analysis also shows that, for most driver mutations investi-
gated here (IDH1/2, ATRX, TP53), tumor grade remains a
prognostic factor in diffuse gliomas with identical driver
mutations. This indicates that IDH-mutated glioblastomas
behave significantly more aggressive than IDH-mutated
grade III gliomas. Although no single molecular marker
was associated with tumor grade, we find that tumor
grade is correlated with the overall mutational load: grade
II gliomas harbour fewer genetic changes than grade III or
IV, even within defined molecular subtypes (e.g. ATRX
mutated gliomas). The increased mutational load may
partially explain the increased aggressiveness of higher
grade gliomas when a subset of the affected genes ac-
tively contribute to gliomagenesis and/or progression.
Materials and methods
For this study, we have used publicly available data from
the TCGA, both lower grade glioma and glioblastoma
datasets. Data include mutation status, copy number
variations and clinical data, only cases with complete
data were included in current analysis (n = 542). All data
analysis were based on overall survival (OS). Survival
data for patients that are listed as <30 days were omitted
from the survival analysis; the cause of death for such
patients may not be tumor-related (but e.g. related to
complications occurring after surgery). EGFR amplifica-
tion status and CDKN2A deletions data were down-
loaded from the cbioportal site [26]. Although such data
could be extracted from the copynumber data (see
below), we used cBioportal data to ensure identical
thresholds were used to define amplification and allelic
loss. All mutation data were filtered for those that result
in a change in the primary amino acid sequence. We
focussed on all genes that are mutated in more than ten
samples of the entire study population We also included
the copy number alterations 1p19q codeletion (loss of
heterozygosity (LOH) of the 1p and 19q chromosome
arms) and trisomy of chromosome 7 and LOH of
chromosome 10 (alt 7/10). Combined, we analysed 128
genetic alterations in 542 samples.
Genome wide SNP 6 Copynumber data was down-
loaded from the TCGA dataportal. This data gives a
value per chromosomal region (segment) where values
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deviating from 0 likely correspond to regions with
chromosomal losses (<0) or gains (>0). From the segment
values, we calculated the average an entire chromosome/
chromosomal arm and defined 1p19q codeletion as aver-
ages over both arms -0.3 or less. When values were dis-
concordant between 1p and 19q or values were between 0
and −0.3 (which can occur in tumors with a high content
of non-neoplastic tissue), we determined 1p19q codeletion
based on visualization of the copynumber plot. This
visualization was performed blinded to the patient out-
come. Alt 7/10 was determined by a value of 0.3 or higher
for chromosome 7 and a value of −0.3 or lower for
chromosome 10. When values were either discordant
between chromosome 7 and 10, or were between 0 and
0.3 for chromosome 7 and/or between 0 and −0.3 for
chromosome 10, we determined alt 7/10 based on
visualization of the copynumber plot (blinded to patient
outcome). Because IDH1 and IDH2 mutations are mu-
tually exclusive and play an identical role in tumor
pathogenesis, we have combined mutation data into an
additional single IDH-mutations variable. Similarly, we
combined EGFR-mutations and EGFR gene amplifica-
tions into a single additional EGFR-alteration variable.
As PIK3CA and PIK3R1 are highly related (and mutu-
ally exclusive) genes within the same PI3-kinase path-
way, we also combined mutation data into an additional
single PI3-kinase mutations variable.
To validate the prognostic value of identified genes,
we performed survival analysis on two additional data-
sets containing mutation and survival data [6, 17]. Haz-
ard ratios (HR) and survival differences were calculated
using a cox proportional hazard model in R (survival
CRAN package), unless specifically indicated otherwise.
Differences in mutation frequencies were calculated
using an ANOVA (3 groups) or T-Test (2 groups). Bon-
ferroni correction was done by using a P value cutoff of
0.0004 (0.05 divided by the total number of calculations
(128 genes and copy number changes)). Chi square tests
were performed using an online calculator (www.
quantpsy.org/chisq/chisq.htm), Graphpad Prism (version
5.00) was used to perform log-rank tests.
Because a large number of genes were tested to de-
termine association with survival, we corrected for
multiple testing by estimating the false positive rate.
This was done by an in-silico analysis in which a set of
100 genes were randomly mutated across 542 samples
(at a population frequency between 2.5-10 %) and we
then calculated how many of those were associated
with survival using the Cox proportional hazards
method. These false positive estimations were made
using three different population mutation frequencies
(2.5 %, 5 % and 10 %) and was done 50 times for each
population mutation frequency. In such analysis, we
identified between 1–12 genes that were significantly
associated with outcome. For all calculations, P < 0.05
was considered statistically significant.
Results
Prognostic classification of diffuse gliomas
We analyzed the combined GBM and LGG (low grade
glioma) datasets from the TCGA (n = 542 samples) and
identified 128 genes that are mutated (non-silent muta-
tions only) in ten or more samples, consistent with a
population frequency >1.7 % (i.e. 10/542 = 1.8 %). Of
these, 57 genes were significantly associated with sur-
vival and the list included the well-known favourable
prognostic markers IDH1/2, 1p19q codeletion, CIC,
FUBP1 and NOTCH1. Poor prognostic markers included
genetic changes in the EGFR locus, PTEN-mutations
and alt 7/10 (Additional file 1 Table S1). IDH1 or IDH2-
mutations (collectively referred to in our analysis as
IDH-mutations unless specifically stated) were associated
with the lowest HR (0.10 95 % confidence interval (CI):
0.07-0.14, P < 0.0001). Because our aim was to generate
a prognostic classification scheme for diffuse gliomas
based on molecular aberrations, the gene with lowest
HR (i.e. IDH-mutations) provided our first molecular
prognostic separator for diffuse gliomas.
Genes associated with prognosis in IDH-wt gliomas
We then screened for prognostic markers separately
within IDH- wildtype (wt) and IDH-mutated gliomas.
Within the subset of IDH-wt gliomas, we identified 4
genes that, when mutated, were significantly associated
with prognosis (Additional file 1: Table S2). However, a
relatively large number of tests were performed to iden-
tify these genes. To correct for multiple testing, we per-
formed similar analysis on a set of 100 genes that were
randomly mutated across the TCGA dataset at a popula-
tion mutation frequency of 2.5 %, 5 % and 10 %. In such
analysis, we identified between 1–12 genes that were sig-
nificantly associated with outcome. Identification of 4/
128 genes associated with survival in IDH wt gliomas is
therefore within the range of the false positive frequency
(1-12 %). By analogy, after Bonferroni correction only
one gene (SLC6A3) remained significant.
As independent validation is warranted, we screened
two additional datasets to confirm the prognostic value
of these four genes in IDH-wt tumors [6, 17]. Clincal
and mutation data are listed in Additional file 1: Tables
S3 and S4. In a dataset of anaplastic astrocytomas, muta-
tions in two of these four genes (PKHD1 and MUC16)
were identified and in a set of GBMs, mutations in three
genes (MUC16, F5 and PKHD1) were identified. Unfor-
tunately, the mutation frequency of individual genes was
too low to allow for a statistical comparison, and a com-
bined analysis of mutated genes does not show a differ-
ence between wt and mutated samples within one
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dataset. However, when combining survival of both data-
sets, mutations in any of these genes is associated with
poor prognosis (median survival of 0.88 v. 1.33 years for
mutated and wt samples respectively, P = 0.018 HR 3.81,
95 % CI 1.26-11.5). However, because numbers are
small, caution should be taken when interpreting these
data as it remains possible that the four prognostic genes
identified in IDH-wt tumors were false positive candi-
dates and do not represent true prognostic genes.
IDH-wt diffuse gliomas are often further subdivided
into those with trisomy on chromosome 7 combined
with LOH of chromosome 10 (alt 7/10) and those with-
out (7/10 wt). It should be noted that, in the TCGA
dataset, alt 7/10 does not confer any prognostic informa-
tion in IDH-wt diffuse gliomas (Additional file 1 Table
S2). On the gene expression levels alt 7/10 GBMs correl-
ate with “classical” GBMs (or those assigned to IGS-18);
7/10 wt tumors associate with other molecular subtypes
(mesenchymal/neural/proneural or IGS-22/IGS-23) [27,
28]. We have therefore screened for prognostic molecular
features within the IDH-wt, alt 7/10 (‘molecular classical’,
n = 214) and within the IDH-wt, 7/10 wt (‘molecular mes-
enchymal’, n = 86) diffuse gliomas. Within molecular clas-
sical gliomas, 10 genes were significantly correlated with
survival (Additional file 1: Table S5) and 11 genes within
the molecular mesenchymal gliomas (Additional file 1:
Table S6). It is interesting to note that TP53 mutations are
associated with a more favourable prognosis in the mo-
lecular classical gliomas and PIK3CA (or combined
PIK3CA and PIK3R1) mutations with poor prognosis in
the molecular mesenchymal gliomas. Unfortunately, we
were unable to validate these results due to an absence of
copy number data in the two validation datasets.
It should be noted that pilocytic astrocytomas (PAs,
brain tumors with favourable prognosis) may be present
among the IDH-wt tumors. However, detailed analysis
shows that only one of the samples included in this
study harboured a genetic profile consistent with PA
(TCGA-HT-7691; a diploid genome apart from a tandem
duplication on chromosome 7q34 involving the BRAF
locus), and the survival data for this patient is 0.1 months
(patient still alive). Omitting this patient from the analysis
will therefore not impact the survival data as presented.
PI3 kinase pathway mutations are associated with poor
survival in molecular astrocytomas
Within IDH-mutated diffuse gliomas, we identified 12/
128 genes associated with poor survival (Additional file
1: Table S7). Mutations in three and two genes of these
were also identified in validation datasets of anaplastic
astrocytomas and GBMs respectively [6, 17]. In both
datasets, there were too few samples to allow compari-
son. The absence of a true validation set indicates that
caution should be taken as it is possible that the twelve
prognostic genes identified in IDH-mutant tumors were
false positive candidates and do not represent true prog-
nostic genes.
IDH-mutated diffuse gliomas are often further sub-
divided into molecular astrocytomas (i.e. those with
mutations in ATRX and/or TP53) and molecular
oligodendrogliomas (i.e. those with 1p19q codeletion)
[16, 23]. It should be noted that these genetic changes by
themselves did not reach statistical significance in IDH-
mutated tumors of the TCGA. This is likely due to the
large number of patients alive at time of analysis (205 pa-
tients alive out of the 243 IDH-mutant glioma patients).
We therefore separated IDH-mutated samples into those
with TP53 or ATRX mutations (n = 151) and those with
1p19q codeletion (n = 74). Seventeen samples had neither
genetic change and five samples had both.
A
B
Fig. 1 PI3-kinase mutations are prognostic in molecular astrocytomas
(diffuse gliomas with ATRX and/or TP53 mutations). a Data from TCGA
samples (test cohort). Histology and grade of samples presented are
listed in Additional file 1: Table S11; b Data from two validation cohorts
(combined) from astrocytomas [17] and glioblastomas [6]. In both
figures, only samples with an IDH mutation and TP53 or ATRX were
selected. In these molecular astrocytomas, PI3 kinase mutations are
prognostic for overall survival. P values indicated are calculated using
the Log-rank test. Number of samples analysed are N = 144 (PIK3 wt)
and N = 13 (PIK3 mutant) for the TCGA cohort and N = 22 (PIK3 wt) and
N = 12 (PIK3 mutant) for the validation cohort
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Within molecular oligodendrogliomas we identified 1
out of 128 genes associated with survival (Additional file
1: Table S8). Unfortunately, there are no external data-
sets to validate this finding.
Within molecular astrocytomas, we identified 8 genes
associated with survival (Additional file 1: Table S9).
PIK3CA was one of the genes identified. Interestingly, a
similar trend was observed in a highly related gene,
PIK3R1, HR 2.45 P = 0.075 95 % CI 0.91 – 6.56. As
PIK3CA and PIK3R1 are highly related (and mutually
exclusive) genes within the same PI3-kinase pathway, we
combined mutation data into an additional single PI3-
kinase mutations variable. The median survival in mo-
lecular astrocytomas with PI3-kinase mutations was
3.7 years v. 6.3 years for PI3-kinase wt molecular astro-
cytomas (P = 0.02, HR 2.93, 95 % CI 1.16 – 7.38, Fig. 1a).
Individual PI3-kinase mutations are listed in Additional
file 1: Table S10. PIK3CA mutations are missense muta-
tions or in-frame deletions and often affect the known
hotspots of the protein (E542, E545 or the C-terminal
domain, see [29]). PIK3R1 mutations are more heteroge-
neous (in-frame deletions, nonsense, frame-shifts, splice
site or missence) not confined to specific hotspots.
To validate the prognostic value of identified genes,
we screened an anaplastic astrocytomas dataset and de-
termined survival within defined molecular subtypes of
diffuse glioma [17]. Within the IDH-mutated and TP53
or ATRX mutated tumors, mutations in four genes out
of the 15 identified in the TCGA dataset (PIK3R1,
PKHD1, NEB1, and NOTCH2) were identified. Of these,
tumors with PIK3R1 mutations (n = 4) had poorer prog-
nosis than PIK3R1 wt tumors (n = 20), median survival
2.4 and 5.4 years respectively (Additional file 2: Figure
S1a). We next downloaded mutation data of a cohort of
GBMs [6]. Also in this dataset, we observed a similar
poor prognostic trend for PIK3R1 mutations in IDH-
mutated and TP53 or ATRX mutated GBMs: Tumors
with PIK3R1 mutations (n = 2) had poorer prognosis
than PIK3R1 wt tumors (n = 2), median survival 1.4 and
5.5 years respectively (Additional file 2: Figure S1b). Al-
though significance was not reached in either of these
datasets (perhaps due to the small sample size), a pure
molecular classification allows combining both datasets.
When this is performed, a median survival of 1.9 v.
5.4 years was observed for PIK3R1 mut and PIK3R1 wt tu-
mors respectively, HR 17.0, 95 % CI (2.40-121), P = 0.0046
(Fig. 1). The fact that PI3-kinase mutations showed similar
trends in prognosis in three independent datasets, strongly
suggests they are prognostic markers for molecular
astrocytomas.
Tumor grade remains prognostic in molecular diffuse
glioma subtypes and is associated with mutational load
of the tumor
Apart from the pure molecular analysis described above,
several clinical and histological parameters are also asso-
ciated with survival. For example, tumor grade is in-
versely correlated with patient survival within the
defined histological subtypes of diffuse glioma [3]; a
Table 1 tumor grade is inversely correlated with patient survival within histological subtypes of diffuse glioma
Grade II survival (y) Grade III survival (y) HR 95 % CI P
Astrocytoma 5.2 3.7 0.27 0.06–1.16 0.078
Oligodendroglioma 7.9 5.2 0.49 0.2–1.2 0.12
Oligoastrocytoma 5.3 6.3 0.26 0.08–0.84 0.024
Survival: median overall survival in years. HR calculated using Cox univariate analysis. HR was calculated grade II vs grade III
Table 2 Frequency of genetic changes listed per histological subtype and grade
Low grade Molecular Oligodendroglioma Molecular Astrocytoma Molecular glioblastoma
IDH1/IDH2 CIC/FUBP1 LOH 1p19q ATRX TP53 EGFR alterations PTEN alt 7/10 NF1 N
OD II 95 48 51 28 28 0 2 3 2 65
OD III 82 49 60 18 27 7 2 7 7 45
A II 83 0 0 67 73 0 0 0 0 30
A III 62 1 1 41 65 26 13 26 15 68
OA II 95 14 21 69 74 0 0 2 5 42
OA III 74 10 13 48 58 16 6 16 3 31
GBM 5 0 0 5 30 55 31 71 10 261
N 228 64 74 131 222 170 93 214 44 542
The numbers in the table are percentages of the number of samples mutated (i.e. population frequencies) except the columns listed as N where absolute numbers
are given.
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correlation that was also present in the TCGA dataset.
(Table 1, Additional file 2: Figure S2).
As detailed above, an alternative method for histo-
logical classification is to classify gliomas based on
their genetic aberrations. Within defined molecular
subtypes (i.e. all tumors that harbour mutations in one
of the lineage specific genes IDH, CIC, FUBP1, ATRX,
TP53, PTEN, EGFR, 1p19q codeletion or alt 7/10, fre-
quency listed in Table 2) tumor grade often remained
inversely correlated with survival (Additional file 2:
Figure S3, Table 3). For example, there were 151 IDH
+ ATRX/TP53-mutated gliomas in the TCGA diffuse
glioma datasets of which 73 were of grade II, 65 of
grade III and 13 of grade IV (GBM) and median sur-
vival was 7.3, 5.2 and 2.8 years (P = 0.0024). Similar
trends were observed for most other single molecular
changes (i.e. selecting samples only on one genetic
change, regardless of other molecular changes present).
Importantly, tumor grade was a prognostic factor for
each of the molecular subtypes identified above: i)
IDH-wt gliomas; ii) IDH and TP53 and/or ATRX-mutated
gliomas and; iii) IDH and 1p19q codeleted gliomas
(Fig. 2).
Because tumor grade was associated with patient sur-
vival, we further analysed the TCGA dataset to identify
the molecular correlates of tumor grade. When screen-
ing for mutations that occur at different frequencies be-
tween grade II and III diffuse gliomas, the only genes
identified were the lineage specific genetic changes
(IDH, CIC, 1p19q co-deletion, ATRX, EGFR, and alt 7/10).
These genes are listed in Table 2 and such a higher rate
(where the frequency of mutations in grade II > grade III)
has been observed in other studies [30, 31] (although
other studies did not find such a difference [14]). Perhaps
the most striking difference between tumors of different
grade however was the total number of genetic changes
(the mutational load). For example, the average number of
non-silent (i.e. those that result in a change in the primary
protein sequence) genetic changes in grade II astrocyto-
mas was 18.8 ± 13.1 (n = 30), in grade III astrocytomas it
was 36.8 ± 47.6 (n = 68), P = 0.0050 (Table 4). This in-
crease in ‘mutational load’ was also observed within mo-
lecular subtypes of diffuse glioma and is listed in Table 5.
For example, the mutational load of ATRX mutated gli-
omas increased from 21.6 ± 10.3 and 26.0 ± 11.2 to 65.4 ±
Table 3 Tumor grade is inversely correlated with survival within molecular subtypes of diffuse glioma
Grade II Grade III Grade IV
Genes OS (y) n OS (y) n OS (y) n P P II vs III
IDH + CIC/FUBP1/LOH 1p19q "not reached" 47 5.2 34 1 0.040 0.04
IDH + ATRX/TP53 7.3 73 5.2 70 2.8 13 0.0029 0.069
EGFR/PTEN/ alt 7/10 1.9 3 1.5 32 1.2 211 0.13 0.5
NF1 2.1 3 1.9 14 1 27 0.034 NA
IDH + CIC/FUBP1/LOH 1p19q refers to mutations in IDH plus any of the subsequent genes, similar for IDH + ATRX/TP53. Statistical tests were performed using a
Chi-square test. OS refers to median overall survival in years. Frequency comparisons were done between grade II, III and IV. Exceptions were made for genes with
too few/no data in one of the grades (e.g. there are no grade IV tumors with 1p19q codeletion). Therefore, the P value for NF1 is based on comparison between
grade III and IV and the P value for IDH + CIC/FUBP1/LOH 1p19q is based on a comparison between grade II and III
Fig. 2 Survival in prognostic molecular subtypes of diffuse glioma stratified by tumor grade. Different subtypes are indicated above each graph.
As can be seen, within defined molecular subtypes, tumor grade remains a prognostic factor. Number of samples (grade II, III and IV) for each
graph: 10, 42 and 248 (IDH-wt); 73, 65 and 13 (IDH-mut, ATRX/TP53 mut); 42, 32 and 0 (IDH-mut, 1p19q codeleted). 17 samples were IDH-mut but
had neither ATRX/TP53 mutations nor 1p19q codeletion. P values indicated are calculated using the Log-rank test; other test for significance show
for IDH-wt tumors a P = 0.0092 and for IDH-mut, ATRX/TP53 mut tumors a P = 0.0034 (both logrank test for trend); for IDH-mut, 1p19q codeleted)
a P = 0.28 (Gehan Breslow Wilcoxon test). Log rank P values for grade II v. III are 0.43 and 0.063 for IDH-wt and IDH-mut, ATRX/TP53 mut
tumors respectively
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40.1 mutations per sample (P < 0.0001) for grade II, III
and IV gliomas respectively.
The mutational load is associated with patient age
Because age is a well-known prognostic factor in diffuse
glioma patients, we included age in the analysis. Similar
to previously reported [1, 32, 33], grade II tumors occur
in patients that were younger than those with grade III
or grade IV tumors, 39.6 ± 12.5 (n = 137), 45.6 ± 13.5 (n
= 144) and 61.3 ± 13.0 (n = 261) years respectively (aver-
age ± standard deviation (SD), P < 0.0001 for any com-
parison, ANOVA). As patient age and tumor grade were
correlated, and tumor grade was correlated to the muta-
tional load, it is not surprizing that age was also corre-
lated with the mutational load of the tumor (Fig. 3). This
correlation was observed not only in the entire dataset
but also within histologically and molecularly defined
subtypes (Tables 5 and 6). Indeed, when analysing the
type of mutations that occur in the TCGA dataset, a
large proportion (2962/9281, 32 %) of all mutations were
C > T transitions in the sequence xCG (where x repre-
sents any nucleotide). Only 4/96 possible combinations
would lead to this specific mutation, and this type of sig-
nature has been identified as an age related mutation
signature [34].
Univariate analysis confirmed that histology (oligoas-
trocytoma vs. oligodendroglioma: P = 0.41 HR 1.33 95 %
CI 0.68-2.61; astrocytoma vs. oligodendroglioma: P =
0.0029 HR 2.52 95 % CI 1.37-4.63; GBM vs oligodendro-
glioma: P = <0.0001 HR 10.6 95 % CI 6.47-17.3), tumor
grade (grade III vs. II: P = 0.0001, HR 3.14 95%CI 1.76-
5.60; grade IV vs. II: P < 0.0001, HR 14.4 95%CI 8.48-
24.5), the number of mutations (P < 0.00001, HR 4.52,
95%CI 3.42 – 5.97) and patient age (P < 0.00001, HR
5.51, 95%CI 4.03 – 7.54) were associated with patient
overall survival. In a multivariate analysis, the number of
mutations remained a significant prognostic factor when
including histology and tumor grade in the analysis.
However, when the multivariate analysis also included
patient age, the number of mutations was no longer a
significant prognostic marker (Table 7). Similar results
were obtained when performing multivariate analysis
within defined molecular subtypes (mutations in IDH,
CIC or FUBP1, TP53, EGFR, PTEN, NF1 or trisomy of
Chr7 combined with LOH of Chr 10 or 1p19q codele-
tion), data not shown. Therefore, patient age appears to
be stronger associated with patient survival than muta-
tional load.
Discussion and conclusions
In this study, we have aimed to identify genetic changes
associated with patient prognosis within defined histo-
logical and molecular subtypes of diffuse glioma by ana-
lysing the TCGA glioma datasets. Our analysis shows
that diffuse gliomas are first classified based on their IDH-
mutation status. Further stratification into molecular
Table 4 Tumor grade is correlated with mutational load within histological subtypes of diffuse glioma
Grade II Grade III Grade IV P
Oligodendroglioma 21.8 ± 10.3 (65) 28.1 ± 13.5 (45) 0.011
Astrocytoma 18.8 ± 13.1 (30) 36.8 ± 47.6 (68) 0.0050
Oligoastrocytoma 20 ± 9 (42) 29.3 ± 14.3 (31) 0.0025
GBM 57.3 ± 19.9 (261)
Values are listed as the average number of non-silent mutations +/− SD (number of tumors analyzed. P values were calculated using an anova
Table 5 Tumor grade is correlated with mutational load within molecular subtypes of diffuse glioma
Grade II Grade III Grade IV P P II v. III
Overall 20.6 ± 10.6 (137) 32.4 ± 34.3 (144) 57.3 ± 19.9 (261) <0.0001
IDH1/IDH2 21.1 ± 10.1 (127) 26.7 ± 12.1 (102) 52 ± 22.1 (13) <0.0001 0.00023
CIC/FUBP1 21.9 ± 10.3 (37) 28 ± 10.7 (26) 0.030
LOH 1p19q 21.7 ± 10.1 (42) 28.2 ± 10.2 (32) 0.0081
ATRX 21.6 ± 10.3 (67) 26 ± 11.2 (51) 65.4 ± 40.1 (14) <0.0001 0.034
TP53 21.4 ± 10.2 (71) 33 ± 46.1 (74) 60.5 ± 23 (78) <0.0001 0.038
EGFR 41.9 ± 12.7 (15) 60.3 ± 16.6 (69) <0.0001
PTEN 42.8 ± 10.8 (12) 62.7 ± 21.3 (80) <0.0001
alt 7/10 24 ± 10.6 (3) 43.5 ± 10.1 (26) 59.6 ± 16.7 (185) <0.0001
NF1 12 ± 7.2 (3) 57.6 ± 101.6 (14) 56.6 ± 15.5 (27) 0.97
Values are listed as the average number of non-silent mutations +/− SD (number of tumors analyzed). Alt 7/10: Trisomy chromosome 7 and LOH of chromosome
10. P values were calculated using an anova. P II v. III indicates significance of grade II v. grade III tumors based on a T-test. Total number of cases analysed = 542
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oligodendrogliomas and molecular astrocytomas involves
determining the ATRX and/or TP53 mutation status or
determining 1p19q codeletion (these changes are mutually
exclusive). Within molecular astrocytomas, mutations in
PI3 kinase genes PIK3CA and PIK3R1 are likely to be as-
sociated with poor prognosis. Additional prognostic fac-
tors include tumor grade and patient age, both of which
are correlated to the mutational load of the tumor. A
scheme for the prognostic classification is proposed in
Fig. 4.
A novel prognostic marker identified by current ana-
lysis are PI3 kinase mutations. Such mutations are fre-
quently observed in various cancer types including
diffuse gliomas [29, 35]. They act as lipid kinase down-
stream of various receptor tyrosine kinases, ultimately
resulting in activation of signalling cascades involved in
cell growth and proliferation, survival and migration
[36]. It has been speculated that, as PI3 kinase mutations
are frequently observed in diffuse gliomas, specific inhib-
itors may provide clinical benefit for PI3 kinase mutated
diffuse glioma patients [37]. Here we show that PI3 kin-
ase mutations also act as prognostic markers for mo-
lecular astrocytoma patients, providing the first evidence
to demonstrate they are associated with poor outcome
within a defined glioma subtype.
Our analysis also shows that grade is associated with
mutational load of the tumor. This is an interesting ob-
servation as the mutational load may provide a bio-
logical explanation for tumor grade. Even if only a
subset of the affected genes contributes to gliomagenesis
and/or progression, an increase in mutational load
would increase tumor aggressiveness. Indeed, several
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Fig. 3 Correlation between patient age and mutational load in diffuse gliomas. The number of non-silent genetic changes increases with patient
age. This increase is irrespective of histological subtype (not shown) or tumor grade. Two samples (out of the 542 analyzed) with a high mutational
load fall outside the y-axis limit in this figure: a grade III astrocytoma, age 47, mutational load 408 and a GBM, age 45, mutational load 181
Table 6 Tumor grade is correlated with patient age within molecular subtypes of diffuse glioma
Grade II Grade III Grade IV P P II v. III
Overall 39.6 ± 12.5 (137) 45.6 ± 13.5 (144) 61.3 ± 13 (261) <0.0001
IDH1/IDH2 39.6 ± 12.3 (127) 42 ± 12.1 (102) 39.6 ± 15.7 (13) 0.32 0.14
CIC/FUBP1 42.3 ± 13.4 (37) 48 ± 10.8 (26) 0.065 0.065
LOH 1p19q 42 ± 12.4 (42) 49.4 ± 11.8 (32) 0.012 0.012
ATRX 37.4 ± 11.9 (67) 38.1 ± 11.3 (51) 41.6 ± 17.2 (14) 0.30 0.74
TP53 37.2 ± 11.8 (71) 39.9 ± 11.7 (74) 59.2 ± 15.5 (78) <0.0001 0.18
EGFR 61.7 ± 7.5 (15) 61.2 ± 11.7 (69) 0.84
PTEN 56.8 ± 10.5 (12) 62.8 ± 11.9 (80) 0.092
alt 7/10 49.7 ± 8.3 (3) 59.4 ± 6.8 (26) 62.8 ± 10.8 (185) 0.015
NF1 51 ± 18.4 (3) 43.7 ± 12.7 (14) 64.4 ± 13.2 (27) 0.00050
Values are listed as the mean patient age +/− standard deviation (number of tumors analysed). P values were calculated using an anova. P II v. III indicates
significance of grade II v. grade III tumors based on a T-test. Total number of cases analysed = 542
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studies on genes mutated at a low population frequency
(‘low frequency genes’) have demonstrated that they can
contribute to tumor formation or progression [38–43].
In a larger study, we have shown that many (but not all)
mutations in low frequency genes affect their functional
property [44]. In addition, mouse experiments have
demonstrated that the age of the cells in which a glioma
is generated largely determines their survival and not
the age of the mouse into which the tumor is trans-
planted. These data argue for an intrinsic (age-related)
property of the tumor initiating cell, perhaps mutational
load [45]. Interestingly however, in a multivariate analysis,
the mutational load is no longer a significant prognostic
marker when patient age is included. The mutational load
therefore cannot fully explain the increased aggressiveness
of tumors of higher grade.
Our analysis also indicates that each malignancy grade
is associated with a different prognosis within molecu-
larly similar tumors. These results appear to be in con-
trast with a recent publication that failed to identify
differences in survival between grade II and III IDH-
mutant astrocytic tumors [24]. Similarly, a second
paper found only a modest impact of tumor grade in
IDH-mutated grade II and III gliomas [25]. However,
our analysis included all tumor grades (II-IV) whereas
those studies focussed only on grade II and III. In
addition, our analysis did not preselect for a specific
histological subtype.
It is often reported that IDH1 mutated GBMs have a bet-
ter prognosis than IDH1-wt gliomas [6, 12]. The analysis
presented here (using TCGA data) also shows that IDH1
mutated grade IV tumors have a poorer prognosis than
IDH1-mutated lower grade gliomas, which has also been
observed in other studies. For example, IDH1 mutated
GBMs have a survival in the range of 24–30 months
whereas IDH1 mutated grade III astrocytic tumours, me-
dian survival is significantly longer surpassing 50–60
months [7, 12] and similarly, IDH1-wt GBMs have median
survival of 11–15 months whereas IDH1-wt grade III astro-
cytic tumours have a median survival in the range of
21 months [12]. Here we show that the correlation between
grade and prognosis is also true for other molecularly simi-
lar tumors. These data therefore argue for inclusion of
tumor grade as prognostic factor when molecularly classi-
fying diffuse gliomas and indicate that molecularly similar
tumors of different grade should not be treated identical.
Additional files
Additional file 1: Table S1. Genetic changes associated with survival in
the entire TCGA (GBM and LGG) datasets. Table S2. Genetic changes
associated with survival in IDH-wt gliomas. Table S3. Validation data from
Parsons et al. Table S4. Validation data from Killela et al. Table S5.
Genetic changes associated with survival in IDH-wt, alt 7/10. Table S6.
Fig. 4 Proposed scheme for the prognostic classification of diffuse
gliomas. Diffuse gliomas are first stratified based on their IDH-
mutation status. Further classification is based on the ATRX and/or
TP53 mutation status or determining 1p19q codeletion (these
changes are mutually exclusive). Within the ATRX and/or TP53
mutated samples, mutations in PI3 kinase genes PIK3CA and PIK3R1
are associated with poor prognosis. It should be noted that there
are genetic changes that associate with each molecular subtype (like
EGFR amplification with IDH-wt tumors). They are however, not
important for prognostic classification and may occur in several
molecular subtypes. For example, PI3K mutations occur in all
molecular subtypes but are only significantly prognostic in IDH-
mutated, TP53/ATRX mutated diffuse gliomas). Additional prognostic
factors include tumor grade and patient age, both of which are
correlated to the mutational load of the tumor and are listed below
the classification scheme. These additional markers are often
correlated to the mutational profile of the tumors: Patients with IDH-
wt tumors are often older and most are diagnosed as grade IV.
ATRX/TP53 indicates mutation of either/both genes; 1p19q indicates
codeletion of these chromosomal arms
Table 7 multivariate Cox analysis of prognostic markers for
overall survival in diffuse glioma patients
HR P value 95 % CI
Histology 1.00
Oligoastrocytoma vs. oligodendroglioma 1.53 0.22 0.78–3.02
Astrocytoma vs. oligodendroglioma 2.19 0.015 1.17–4.11
Grade 1.00
III vs. II 2.46 0.0040 1.33–4.54
IV vs. II* 6.41 <0.0001 2.11–4.57
Age 1.00
> 50 vs. ≤50 3.10 <0.0001 2.11–4.57
Mutational load 1.00
> 40 vs. ≤ 40 0.69 0.066 0.47–1.03
A total of 542 samples were analyzed for this table. HR: Hazard Rate; CI:
Confidence interval. Grade levels were 2, 3 and 4. Three histology levels were
used (oligodendroglioma, oligoastrocytoma and astrocytoma), GBMs were
categorized as astrocytomas
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Genetic changes associated with survival in IDH-wt, 7/10 wt. Table S7.
Genetic changes associated with survival in IDH-mutant gliomas. Table S8.
Genetic changes associated with survival in IDH and 1p19q. Table S9.
Genetic changes associated with survival in IDH and TP53/ATRX mutated
gliomas. Table S10. Table S11. Histological subtypes in molecular
astrocytomas stratified by PI3-kinase mutations. (XLSX 145 kb)
Additional file 2: Figure S1. PI3-kinase mutations are prognostic for
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